Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN P BERDAHL

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1871761577
CMS profile
130878
Location
SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$176,679.11

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $172,303.00 35
Food and Beverage $2,573.91 45
Travel and Lodging $1,802.20 5

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN P BERDAHL

NPI 1871761577 · CMS profile ID 130878

Allopathic & Osteopathic Physicians / Ophthalmology

SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871761577?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871761577?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871761577?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1871761577?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $176,679.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dompe US, Inc. $17.8306/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947218933 CMS
GLAUKOS CORPORATION $2,000.0005/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964408671 CMS
Alcon Research LLC $700.0005/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920371955 CMS
Oyster Point Pharma, Inc. $24.0005/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946023897 CMS
Sight Sciences, Inc. $750.0005/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960224767 CMS
Rayner Intraocular Lenses Limited $12.9905/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910486273 CMS
Alcon Vision LLC $2,800.0005/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212703 CMS
Johnson & Johnson Surgical Vision, Inc. $625.0005/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887171783 CMS
GLAUKOS CORPORATION $3,250.0005/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964399283 CMS
GLAUKOS CORPORATION $32.8605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964401587 CMS
GLAUKOS CORPORATION $26.2905/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964406847 CMS
Kala Pharmaceuticals, Inc. $15.0104/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892855479 CMS
Carl Zeiss Meditec USA, Inc. $36.7404/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935305807 CMS
Carl Zeiss Meditec, Inc. $120.5604/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965507919 CMS
Alcon Vision LLC $31.5104/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905022815 CMS
Alcon Vision LLC $2,100.0004/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212695 CMS
Alcon Vision LLC $2,100.0004/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212697 CMS
Novartis Pharmaceuticals Corporation $21.4404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893527991 CMS
GLAUKOS CORPORATION $2.8103/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964401581 CMS
GLAUKOS CORPORATION $15.2003/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964401583 CMS
GLAUKOS CORPORATION $6.6903/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964401585 CMS
Alcon Vision LLC $39.5403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905022831 CMS
Mallinckrodt Hospital Products Inc. $23.1503/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937476559 CMS
Alcon Vision LLC $150.0003/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905033965 CMS
Alcon Vision LLC $3,750.0003/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212707 CMS
Alcon Vision LLC $11.5902/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905022809 CMS
Alcon Vision LLC $700.0002/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212681 CMS
Alcon Research LLC $50,000.0002/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920371967 CMS
Carl Zeiss Meditec Cataract Technology Inc. $13.0302/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 862642083 CMS
Johnson & Johnson Surgical Vision, Inc. $1,250.0002/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887171773 CMS
Alcon Vision LLC $1,625.0002/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920212693 CMS
Alcon Vision LLC $36.2101/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905022823 CMS
Allergan, Inc. $34.5501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889845451 CMS
GLAUKOS CORPORATION $200.7001/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964401589 CMS
Sight Sciences, Inc. $34.8401/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960213487 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $160,767.43 117
PY2020 $141,870.19 58
PY2021 $232,125.34 80
PY2022 $176,679.11 85
PY2023 $167,828.36 105
PY2024 $198,406.06 99
PY2025 $134,175.18 94

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $526,683.74 94
PY2024 Principal investigator $911,748.47 469
PY2023 Principal investigator $736,016.38 172
PY2022 Recipient $108.50 1
PY2022 Principal investigator $337,192.11 53
PY2021 Principal investigator $519,228.22 81
PY2020 Principal investigator $575,164.46 72
PY2019 Recipient $22,593.79 3
PY2019 Principal investigator $558,559.20 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $11,024.53 12/31/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202532887
Principal investigator 1 Glaukos Corporation $2,270.00 12/10/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906189
Principal investigator 1 Glaukos Corporation $90.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910551
Principal investigator 1 Glaukos Corporation $3,880.00 11/19/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Follow-up of Eyes that Received Epithelium-on Corneal Collagen Cross-Linking Treatment in Study GLK-202-04 No dispute reported 06/30/2026 1250906016
Principal investigator 1 Glaukos Corporation $8,295.00 11/19/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906181
Principal investigator 1 Glaukos Corporation $360.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910543
Principal investigator 1 Glaukos Corporation $731.89 10/15/2025 Non-covered Recipient Entity
Konan Medical, USA, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907486
Principal investigator 1 Glaukos Corporation $9,530.00 10/08/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906173
Principal investigator 1 Glaukos Corporation $1,440.00 10/08/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906177
Principal investigator 1 Glaukos Corporation $2,895.00 09/17/2025 Non-covered Recipient Entity
Konan Medical, USA, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907482
Principal investigator 1 Glaukos Corporation $2,190.00 09/10/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906157
Principal investigator 1 Alcon Research LLC $1,000.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924320
Principal investigator 1 Alcon Research LLC $500.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924322
Principal investigator 1 Alcon Research LLC $2,000.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924324
Principal investigator 1 Alcon Research LLC $1,000.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924340
Principal investigator 1 Alcon Research LLC $750.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924342
Principal investigator 1 Alcon Research LLC $1,500.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1220924344
Principal investigator 1 Alcon Research LLC $706.44 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069398
Principal investigator 1 Alcon Research LLC $106,074.38 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069400
Principal investigator 1 Alcon Research LLC $2,218.18 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069402
Principal investigator 1 Alcon Research LLC $10,911.22 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069404
Principal investigator 1 Alcon Research LLC $40,383.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069406
Principal investigator 1 Alcon Research LLC $6,027.36 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069408
Principal investigator 1 Alcon Research LLC $11,213.68 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069410
Principal investigator 1 Alcon Research LLC $2,657.50 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069412
Principal investigator 1 Alcon Research LLC $3,807.76 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069414
Principal investigator 1 Alcon Research LLC $2,825.76 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069416
Principal investigator 1 Alcon Research LLC $437.08 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069418
Principal investigator 1 Alcon Research LLC $1,412.88 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069420
Principal investigator 1 Alcon Research LLC $62.70 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069422
Principal investigator 1 Alcon Research LLC $6,945.88 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069424
Principal investigator 1 Alcon Research LLC $395.57 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069426
Principal investigator 1 Alcon Research LLC $593.35 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069428
Principal investigator 1 Alcon Research LLC $11.80 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069430
Principal investigator 1 Alcon Research LLC $12.60 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069432
Principal investigator 1 Alcon Research LLC $44.05 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069434
Principal investigator 1 Alcon Research LLC $11.66 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069436
Principal investigator 1 Alcon Research LLC $706.44 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069438
Principal investigator 1 Alcon Research LLC $706.44 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069440
Principal investigator 1 Alcon Research LLC $45,743.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069442
Principal investigator 1 Alcon Research LLC $1,109.09 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069444
Principal investigator 1 Alcon Research LLC $10,911.22 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069446
Principal investigator 1 Alcon Research LLC $3,013.68 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069448
Principal investigator 1 Alcon Research LLC $3,807.76 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069450
Principal investigator 1 Alcon Research LLC $706.44 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069452
Principal investigator 1 Alcon Research LLC $706.44 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069454
Principal investigator 1 Alcon Research LLC $45,743.00 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069456
Principal investigator 1 Alcon Research LLC $1,109.09 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069458
Principal investigator 1 Alcon Research LLC $5,455.61 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069460
Principal investigator 1 Alcon Research LLC $3,013.68 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069462
Principal investigator 1 Alcon Research LLC $3,807.76 08/28/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
User Product Evaluation Protocol No dispute reported 06/30/2026 1237069464
Principal investigator 1 Glaukos Corporation $90.00 08/13/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910819
Principal investigator 1 Glaukos Corporation $1,200.00 08/06/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906153
Principal investigator 1 ABBVIE INC. $13,579.00 08/05/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION CLINIC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202501980
Principal investigator 1 Glaukos Corporation $270.00 07/16/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910747
Principal investigator 1 Glaukos Corporation $4.71 07/09/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250908936
Principal investigator 1 Glaukos Corporation $1,130.00 07/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906151
Principal investigator 1 Glaukos Corporation $5,645.00 07/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906170
Principal investigator 1 Glaukos Corporation $1,250.00 07/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906321
Principal investigator 1 Glaukos Corporation $517.24 06/04/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250903988
Principal investigator 1 Glaukos Corporation $1,200.00 06/04/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906146
Principal investigator 1 Glaukos Corporation $1,286.62 06/04/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906306
Principal investigator 1 Glaukos Corporation $270.00 06/04/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910737
Principal investigator 1 Glaukos Corporation $805.00 05/07/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906143
Principal investigator 1 Glaukos Corporation $40,775.00 05/07/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906161
Principal investigator 1 Glaukos Corporation $375.00 05/07/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250906166
Principal investigator 1 Glaukos Corporation $3,950.00 05/07/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906301
Principal investigator 1 Glaukos Corporation $450.00 04/29/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910729
Principal investigator 1 Glaukos Corporation $517.24 04/02/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904539
Principal investigator 1 Glaukos Corporation $980.00 04/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906617
Principal investigator 1 Glaukos Corporation $2,500.00 04/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906724
Principal investigator 1 Glaukos Corporation $5,000.00 04/02/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906788
Principal investigator 1 Glaukos Corporation $231.00 03/25/2025 Non-covered Recipient Entity
InComm Digital Solutions, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250907572
Principal investigator 1 Glaukos Corporation $2.66 03/19/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250909323
Principal investigator 1 ABBVIE INC. $650.00 03/13/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION CLINIC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202463104
Principal investigator 1 Alcon Research LLC $28,600.00 03/13/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
Clareon PanOptix Pro: Early bilateral Clinical Experience No dispute reported 06/30/2026 1220924168
Principal investigator 1 Glaukos Corporation $258.62 03/12/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905028
Principal investigator 1 ABBVIE INC. $1,252.00 03/06/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION CLINIC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202456707
Principal investigator 1 Glaukos Corporation $2,470.34 03/05/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906430
Principal investigator 1 Glaukos Corporation $580.00 03/05/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906613
Principal investigator 1 Glaukos Corporation $258.62 02/19/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904916
Principal investigator 1 Glaukos Corporation $421.30 02/19/2025 Non-covered Recipient Entity
Commercial Print Management
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250907816
Principal investigator 1 Glaukos Corporation $1,330.00 02/12/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906609
Principal investigator 1 Glaukos Corporation $8,950.00 02/12/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906721
Principal investigator 1 ABBVIE INC. $12,660.00 02/05/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION CLINIC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202444671
Principal investigator 1 Glaukos Corporation $258.62 01/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904801
Principal investigator 1 Alcon Research LLC $4,000.00 01/09/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
Unity VCS Cataract Claims Study No dispute reported 06/30/2026 1220924162
Principal investigator 1 Alcon Research LLC $1,200.00 01/09/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
Unity VCS Cataract Claims Study No dispute reported 06/30/2026 1220924164
Principal investigator 1 Alcon Research LLC $200.00 01/09/2025 Non-covered Recipient Entity
VANCE THOMPSON VISION
Unity VCS Cataract Claims Study No dispute reported 06/30/2026 1220924166
Principal investigator 1 Glaukos Corporation $258.62 01/08/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905487
Principal investigator 1 Glaukos Corporation $3,405.00 01/08/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906411
Principal investigator 1 Glaukos Corporation $3,320.00 01/08/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250906605
Principal investigator 1 Glaukos Corporation $1,383.23 01/08/2025 Non-covered Recipient Entity
Vance Thompson Vision Clinic, Prof LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250906717
Principal investigator 1 Glaukos Corporation $450.00 01/08/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910947

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $50,050.00 1
PY2024 Value of interest $62,500.00 1
PY2023 Amount invested $50,050.00 1
PY2023 Value of interest $60,000.00 1
PY2022 Amount invested $50,050.00 2
PY2022 Value of interest $80,711.00 2
PY2021 Amount invested $99,950.00 3
PY2021 Value of interest $77,243.90 3
PY2020 Amount invested $49,950.00 2
PY2020 Value of interest $24,518.90 2
PY2019 Amount invested $49,950.00 1
PY2019 Value of interest $16.20 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

10 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 TearOptix, Inc. $50,050.00 $62,500.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1145282167
PY2023 TearOptix, Inc. $50,050.00 $60,000.00 Common Stock and Preferred Stock Physician Covered Recipient No dispute reported 06/30/2026 1039880037
PY2022 RxSight Inc $0.00 $30,661.00 Fully Vested Options Physician Covered Recipient No dispute reported 06/30/2026 958919049
PY2022 TearOptix, Inc. $50,050.00 $50,050.00 Common and Preferred Stock Physician Covered Recipient No dispute reported 06/30/2026 957785969
PY2021 Rapid Pathogen Screening, Inc. $49,950.00 $18.90 common stock Physician Covered Recipient No dispute reported 06/30/2026 760993610
PY2021 RxSight Inc $0.00 $27,225.00 Fully Vested Options Physician Covered Recipient No dispute reported 06/30/2026 849773681
PY2021 TearOptix, Inc. $50,000.00 $50,000.00 Preferred Stock Physician Covered Recipient No dispute reported 06/30/2026 835516489
PY2020 Rapid Pathogen Screening, Inc. $49,950.00 $18.90 common stock Physician Covered Recipient No dispute reported 06/30/2026 737343809
PY2020 RxSight Inc $0.00 $24,500.00 Fully Vested Options Physician Covered Recipient No dispute reported 06/30/2026 752951863
PY2019 Rapid Pathogen Screening, Inc. $49,950.00 $16.20 common stock Physician Covered Recipient No dispute reported 06/30/2026 651528363